Interventional Radiology in Cancer Treatment
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 May 2024) | Viewed by 3109
Special Issue Editors
Interests: interventional oncology; liver directed therapy
Special Issue Information
Dear Colleagues,
Since the first intraarterial liver cancer therapy was performed by Ryusaku Yamada in 1977 and the first percutaneous ablation was performed by Luigi Solbiati in 1982, the field of Interventional Oncology (IO) has grown exponentially. A specialty built on innovation, creativity, and disruptive approaches to medical care has now been adopted worldwide and is practiced as the fourth pillar of cancer care alongside medical oncology, surgical oncology, and radiation oncology. IO therapies for hepatocellular carcinoma (HCC), metastatic neuroendocrine tumors (mNET), and renal cell carcinoma (RCC) have been incorporated into the respective Barcelona Clinic Liver Cancer (BCLC) and National Comprehensive Cancer Network (NCCN) guidelines. Due to the explosion of new technologies and rapid expansion of treatment modalities, keeping referring physicians and patients apprised with regard to what Interventional Radiology can offer can be challenging. This Special Issue will elucidate the current cutting-edge technologies and therapies IO offers, as well as the evidence supporting them.
We look forward to receiving your contributions.
Dr. Sarah B. White
Dr. Amy C. Taylor
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- interventional radiology
- interventional oncology
- hepatocellular carcinoma
- chemoembolization
- radioembolization
- ablation
- cholangiocarcinoma
- metastatic disease
- neuroendocrine tumor
- breast cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.